VCBeat has learned at the earliest opportunity that the intelligent multi-omics technology enterpriseInfinity Scope Multi-Omics Biotechnology Co. Ltd.(hereinafter referred to as “Infinity Scope”) has recently completed its Pre-A financing round of RMB 51 million. This round of financing was led byZhejiang Fresscon CAPITAL Co., Ltd., SUNZ FUND, TigerYeah Capital, Dehua Venture CapitalJoint Participation,Fenghe CapitalServing as the exclusive financial advisor. The funds raised will be primarily used for the research and development of intelligent multi-omics products, clinical trials, and regulatory registration, thereby accelerating the industrialization and commercial expansion of related technologies.

As the first to strategically position itself in China“AI-Powered Multi-Omics” Technical Roadmapan innovative enterprise, Infinity Scope is committed to advancing multi-omics technology from a single detection tool to an intelligent research platform. The company has built a“Hardware + AI + Reagents”an integrated solution centered on [core], achieving a complete technical closed loop from experimental acquisition to data analysis through its self-developed testing equipment platform, AI-driven data analysis system, and high-sensitivity reagent system.

Currently, the company's products and technical services have been widely applied inScientific Research, Drug DevelopmentwithClinical Translationand other fields, having cumulatively served over 100 clients and generated tens of millions of yuan in order revenue, demonstrating strong commercialization momentum.

“Multi-omics technologies” are increasingly recognized as the next-generation key driver of life sciences, following the era of gene sequencing. From genomics and transcriptomics to proteomics and metabolomics, scientists are deciphering the complexity of biological systems on an unprecedented scale. With rapid advancements in detection technologies and computational power, multi-omics research is evolving from single-data acquisition to cross-dimensional data integration, entering a new phase of “AI-powered Multi-omics.”

In recent years, multi-omics detection technologies have continued to achieve breakthroughs. From spatial molecular profiling at the tissue level to highly sensitive biomarker detection in body fluid samples, researchers are able to systematically analyze cellular states and molecular expression across different scales. These technologies enable scientists to observe the spatial relationships between cells and molecules within tissue architectures, as well as to capture dynamic changes in disease-related molecules through body fluid samples such as blood. The rapid accumulation of multidimensional data has provided new research perspectives for investigating complex biological issues, including the tumor microenvironment, immune regulation, and neurological disorders.

Meanwhile, artificial intelligence is becoming a key driver in advancing multi-omics research. AI algorithms enable automated processing and in-depth mining of massive multi-omics datasets, significantly enhancing data analysis efficiency and biological insights across applications ranging from cell typing and molecular network elucidation to disease state prediction. The integration of multi-omics technologies with artificial intelligence is gradually shifting life sciences research from a traditional experiment-driven paradigm to a new model driven by data and algorithms.

According to Ark Invest’s “Big Ideas 2025” report, multi-omics technology is ranked among the most promising innovative technology platforms of the future, alongside artificial intelligence, energy storage, and robotics. AI-driven multi-omics analysis tools are reshaping multiple fields, including drug discovery, precision diagnostics, and precision therapeutics—promising significant improvements in R&D efficiency and driving rapid growth in the medical testing market size.

Amid this technological wave, intelligent multi-omics is gradually becoming a critical technical infrastructure for life sciences research and biomedical innovation.

As life sciences enter the data-driven era, multi-omics technologies are becoming a critical bridge connecting basic research, drug development, and clinical applications. However, achieving large-scale implementation of multi-omics technologies relies not merely on a single detection method, but requires the simultaneous integration of high-precision molecular detection capabilities, scalable reagent systems, and AI-driven data analytics to build a comprehensive technical platform. This highly complex systems engineering endeavor makes intelligent multi-omics platforms one of the most technically demanding frontiers in the life sciences sector.

Addressing this challenge,Infinity Scope has built an integrated intelligent multi-omics platform centered on “hardware + AI + reagents,” achieving a closed-loop workflow that spans sample testing, molecular information acquisition, data analysis, and biological insights. By leveraging its self-developed testing equipment, high-performance reagent systems, and an AI-driven data analysis platform, the company can systematically decode multidimensional molecular information from complex biological samples, transforming massive multi-omics datasets into actionable scientific and clinical insights.

Infinity Scope offers supporting instruments and universal assay kits. Image source: the company’s official WeChat account.

This platform capability is continuously expanding the application scenarios of multi-omics technologies. In the field of innovative drug R&D, multi-omics data is becoming a critical tool for novel target discovery, elucidation of drug mechanisms of action, and patient stratification in clinical trials. In the realm of precision medicine, the integration of multidimensional molecular information with artificial intelligence analysis is poised to drive the development of next-generation companion diagnostics, providing more precise decision-making support for personalized treatment.

Meanwhile, by systematically monitoring molecular changes in vivo, multi-omics technologies also provide new technical pathways for disease risk prediction, early screening, and proactive intervention, enabling medicine to gradually shift from traditional “disease treatment” toward more forward-looking “disease prevention” and “health management.”

In the realm of complex diseases, including neurodegenerative disorders, autoimmune diseases, and aging research, multi-omics data also demonstrate significant application potential. By conducting long-term tracking and systematic analysis of multidimensional molecular information, researchers can identify molecular signals of disease onset at an earlier stage, thereby providing a critical basis for disease prediction, risk assessment, and preventive healthcare strategies.

As intelligent multi-omics platforms involve deep synergy among detection technologies, reagent engineering, and algorithmic systems, their technical barriers are significantly higher than those of single-omics approaches. Leveraging extensive scientific research accumulation and engineering capabilities, Infinity Scope has gradually established a comprehensive platform-based technical system, achieving the transition from a research tool to an industrialized platform.Currently, the company’s technology platform serves numerous top-tier research institutions, hospitals, and leading pharmaceutical enterprises in China, with a cumulative client base exceeding 100 and commercial order volumes continuing to grow.

From an industry perspective, with the rapid development of precision medicine and innovative drug R&D, intelligent multi-omics platforms are poised to become critical technological infrastructure for the future life sciences and healthcare industries, with their potential market space still in a phase of rapid expansion.

The establishment of Infinity Scope stems from the team’s long-term contemplation on the industrialization of multi-omics technologies. The founder of Infinity Scope has long been engaged in cutting-edge multi-omics research, accumulating a profound scientific foundation in spatial omics, proteomics, and related technical fields. Through extensive collaboration with research institutions, hospitals, and pharmaceutical companies, he gradually realized that many promising frontier technologies remain confined to the laboratory stage, still facing a significant gap before they can truly serve scientific research and clinical applications.

As multi-omics technologies gain increasing importance in the fields of life sciences and biomedicine, transforming complex research techniques into stable, scalable products and platforms has become a critical issue for industry development. Against this backdrop, Infinity Scope was established, dedicated to driving the transition of multi-omics technologies from research tools to industrialized platforms.

Grounded in scientific innovation, the team leverages systematic engineering development and product-oriented design to transform complex multi-omics experimental workflows into standardized, scalable technical solutions, thereby achieving a critical transition from research outcomes to industrialized products.

Within less than two years, the company has successfully engineered and implemented its multi-omics technology platform, served over 100 clients, secured commercial orders worth tens of millions of yuan, and preliminarily validated the industrialization potential of intelligent multi-omics technologies in scientific research and pharmaceuticals.

Regarding this financing round,Founder of Infinity ScopeHe stated, “We appreciate the recognition from investment institutions for the Infinity Scope team and our direction in intelligent multi-omics technology. We believe that with the continuous integration of multi-omics technologies and artificial intelligence, life sciences research and the healthcare industry are entering a new data era. In the future, Infinity Scope will continue to strengthen core technology R&D and platform capabilities, further improving its integrated intelligent multi-omics platform featuring ‘hardware + AI + reagents.’ This will promote the practical application of multi-omics technologies in fields such as drug development, precision diagnostics, disease prediction, and health management, providing key technical support for innovation in life sciences and the development of the healthcare industry.”

Zhejiang Fresscon CAPITAL Co., Ltd. Investor“Spatial multi-omics represents a key technological frontier for understanding the complexity of life and disease mechanisms, standing on the eve of an explosion in its transition from scientific research to clinical applications. The team at Infinity Scope not only boasts profound scientific research backgrounds both domestically and internationally, but also demonstrates exceptional capability in commercial implementation and a deep understanding of local customer needs. They have established unique barriers in areas such as data algorithms and wet-lab workflows. We are delighted to lead this round of financing and look forward to working with the company to bring this transformative technology to benefit more research and clinical scenarios.”

SUNZ FUND Investorstated: “We continue to closely monitor upstream life science tool companies capable of addressing ‘chokepoint’ technologies. Infinity Scope has established a comprehensive presence in the field of spatial multi-omics, forming a closed loop that spans sample preparation, high-precision detection, and bioinformatics analysis. Its service quality and data stability have gained widespread recognition from leading hospitals and pharmaceutical companies. Within just one year, the company has consecutively obtained multiple national-level qualifications and industry awards, validating the team’s execution capabilities and technological leadership. We believe that Infinity Scope will become a core force in this field, helping China secure a strategic high ground in the new wave of biotechnology.”

TigerYeah Capital Investors“Spatial multi-omics, serving as a critical technological bridge connecting basic research with clinical translation, is currently in a phase of rapid growth. The team at Infinity Scope has demonstrated exceptional comprehensive capabilities in technology R&D, data algorithms, and commercial implementation. Its deep collaborations with numerous leading hospitals, research institutes, and pharmaceutical companies in China fully attest to the market’s high recognition of its technology platform. As an investor, we value not only the company’s technological barriers but also its potential for continuous innovation and industrial synergy. TigerYeah Capital will leverage its accumulated resources in the healthcare sector to help Infinity Scope accelerate product iteration and market expansion, jointly promoting the application of spatial multi-omics technology across a broader range of research and clinical scenarios.”

Dehua Investors“Spatial multi-omics represents another revolutionary breakthrough in life sciences and precision medicine, following single-cell sequencing. It offers irreplaceable advantages in empowering clinical research, elucidating disease mechanisms, and facilitating the clinical translation of companion diagnostics. We believe that, leveraging its leading technology and service capabilities, Infinity Scope will emerge as a benchmark enterprise in the field of spatial multi-omics.”

Zhejiang Fresscon CAPITAL Co., Ltd. was spun off from Zhejiang New Trunk Line Media Investment Co., Ltd. (hereinafter referred to as “New Trunk Line”) and was jointly established by institutions including New Trunk Line and Baida Group, along with the management team of New Trunk Line. The company’s core personnel are experts with many years of experience in equity investment, and the professional composition of its team covers investment management, financial accounting, law, finance and securities, biomedicine, and the digital economy.

Hunan Linkong Sanze Venture Capital Partnership (Limited Partnership) is the first venture capital fund in the Changsha Free Trade Zone Airport Area. It was jointly established by Hunan Free Trade Zone Airport Industry Investment Group Co., Ltd., Sunz Venture Capital Management Co., Ltd., and other entities. The fund has a total size of RMB 300 million and an operational term of 8 years. As a professional venture capital institution focusing on biomedicine, healthcare, and technological innovation, the company leverages the industrial development advantages of the Changsha Free Trade Zone Airport Area. Adopting the “Fund + Base” model as its core development strategy, it drives deep integration and innovative development of the biomedical and healthcare industry chain through dual empowerment via capital guidance and industrial stimulation. Furthermore, by leveraging resource advantages from government and social capital both within and outside Hunan Province, the firm provides comprehensive post-investment value-added services to portfolio companies, including industrial resource matchmaking and landing incubation. It prioritizes supporting high-quality innovative enterprises in the medical and health sectors to achieve rapid growth, thereby empowering the upgrading of the regional biomedical industry.

TigerYeah Capital, established in 2014, is a controlled subsidiary of Tigermed and its core independent venture capital platform. Registered with the Asset Management Association of China (AMAC) as a private equity and venture capital fund manager, the firm focuses on equity investments in the healthcare and life sciences sector. It currently manages seven RMB-denominated funds, with total assets under management exceeding RMB 2 billion. Having invested in over 150 healthcare projects, TigerYeah Capital has earned widespread industry recognition for its investment performance.The firm focuses on early-stage and growth-stage enterprises in the healthcare sector, with core investment themes centered on innovative medical devices and novel therapeutics. It also maintains deep strategic positions in niche segments such as biotechnology, CROs, healthcare services, and nutrition and wellness. Priority is given to innovative companies possessing core intellectual property, high technological barriers, and potential for import substitution. Investments in the medical device sector account for over 80% of its portfolio, while its novel therapeutics pipeline covers cutting-edge modalities including cell therapy, radiopharmaceuticals, and bispecific antibodies.

Dehua Venture Capital, a subsidiary of Dehua Group—a Top 500 Private Enterprise in China—serves as the group’s professional equity investment platform and is one of the earliest approved venture capital firms in Zhejiang Province. Focusing on technology sectors such as biopharmaceuticals, semiconductors, and high-end manufacturing, the company has invested in more than 20 enterprises, acting as a key capital platform for Dehua Group’s strategic layout in emerging industries.

FengHe Capital, as a boutique investment bank deeply rooted in the healthcare and life sciences sectors, covers fields such as innovative drugs, medical devices, and life sciences. It provides end-to-end private equity financing financial advisory and strategic consulting services, from the angel stage to Pre-IPO rounds. The team members come from top-tier domestic investment banks, investment institutions, and consulting firms, with cumulative transaction amounts exceeding ten billion RMB, possessing deep industry insights and rich transaction experience. FengHe Capital firmly believes that the integration of technology and capital can unlock the infinite potential of human life, and is committed to growing alongside the most innovative enterprises in China's healthcare industry.